Study of Residual Inflammation Risk and Heart Outcomes in Adults Undergoing Coronary Interventions

What this Trial Is About

Coronary heart disease CAD results from reduced blood flow to the heart due to narrowed or blocked coronary arteries. This condition can cause heart muscle damage from lack of oxygen. Despite effective drug treatments after percutaneous coronary interventions PCI, patients with CAD remain at high risk for major adverse cardiovascular events MACE. This study focuses on residual inflammation risk RIR, an important factor linked to worse outcomes in CAD. The study aims to define the RIR standard in Chinese patients undergoing PCI and explore how changes in high-sensitivity C-reactive protein hsCRP levels affect MACE over a 5-year period. Participants in this observational study will have serial hsCRP blood tests at least 4 weeks apart, starting with the first measurement after PCI. The study will track patients over 60 months to observe the impact of RIR on their cardiovascular health. No treatments or interventions are assigned instead, researchers will monitor natural changes in inflammation markers and clinical outcomes. During the study, participants will undergo regular laboratory testing to measure hsCRP and other key health indicators. Researchers will record major cardiovascular events such as heart attacks, strokes, deaths, and bleeding episodes. Participants clinical progress will be followed for five years to assess long-term outcomes related to inflammation and heart disease. This comprehensive monitoring aims to improve understanding of inflammations role in CAD prognosis after PCI.

RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI